Breast cancer stands as the foremost cause of cancer‐related mortality among women, presenting a substantial economic impact on society. The limitations in current therapeutic options, coupled with poor patient tolerance, underscore the urgent need for novel treatments. Our study embarked on a genomic association exploration of breast cancer, leveraging whole‐genome sequencing data from the Finngen database, complemented by expression quantitative trait loci (eQTL) insights from the eQTLGen and GTEx Consortiums. An initial investigation was conducted through summary‐based Mendelian randomization (MR) to pinpoint primary eQTLs. Analysis of blood specimens revealed 103 eQTLs significantly correlated with breast cancer. Focusing our efforts, we identified 19 candidates with potential therapeutic significance. Further scrutiny via two‐sample MR pinpointed UROD, LMO4, HORMAD1, and ZSWIM5 as promising targets for breast cancer therapy. Our research sheds light on new avenues for the treatment of breast cancer, highlighting the potential of genomic association studies in uncovering viable therapeutic targets.

中文翻译：

---

使用孟德尔随机分析和药物靶点预测鉴定乳腺癌的潜在治疗靶点

乳腺癌是女性癌症相关死亡的首要原因，对社会产生巨大的经济影响。当前治疗选择的局限性，加上患者耐受性差，凸显了对新疗法的迫切需要。我们的研究开始了乳腺癌的基因组关联探索，利用 Finngen 数据库的全基因组测序数据，并辅以 eQTLGen 和 GTEx 联盟的表达数量性状位点 (eQTL) 见解。通过基于摘要的孟德尔随机化 (MR) 进行初步调查，以查明主要 eQTL。血液样本分析显示 103 个 eQTL 与乳腺癌显着相关。我们集中精力，确定了 19 种具有潜在治疗意义的候选药物。通过双样本 MR 进行的进一步审查确定 UROD、LMO4、HORMAD1 和 ZSWIM5 是乳腺癌治疗的有希望的靶点。我们的研究揭示了乳腺癌治疗的新途径，强调了基因组关联研究在发现可行的治疗靶点方面的潜力。